StreetInsider.com News Articles

Activist Ananym builds stake in Bio-Techne, urges strategic review - Bloomberg

Mon, 15 Jun 2026 08:49:35 -0400

(Updated - June 15, 2026 8:49 AM EDT)

Activist Ananym builds stake in Bio-Techne (NASDAQ: TECH), urges strategic review - Bloomberg

Ananym Capital Management has built a stake in Bio-Techne, and is pushing for a strategic review process that could include a potential sale of the company, according to reporting from Bloomberg
In a letter to Bio-Techne's board, Ananym pointed to the stock's underperformance versus peers and the broader market.
The activist said a sale of the company would provide more value than Bio-Techne could create standalone.

Piper Sandler Starts Bio-Techne Corp. (TECH) at Neutral

Thu, 11 Jun 2026 05:38:52 -0400

(Updated - June 11, 2026 5:38 AM EDT)

Piper Sandler analyst David Westenberg initiates coverage on Bio-Techne Corp. (NASDAQ: TECH) with a Neutral rating and a price target of $65.00.

The analyst comments: “We initiate coverage of Bio-Techne (TECH) with a Neutral rating and $65 PT. We believe Bio-Techne has the most impressive margins profile with a focus on high value reagents. While we believe such a profitable business is susceptible to competitive pressure, Bio-Techne has unique vertical integrated manufacturing, closed in razor/razor blade instrumentation and specialized offerings. While Bio-Techne maintains best-in-class margins and a dominant position in protein reagents, the Street

Piper Sandler Starts Bio-Techne Corp. (TECH) at Neutral

Thu, 11 Jun 2026 05:38:52 -0400

(Updated - June 11, 2026 5:38 AM EDT)

Piper Sandler analyst David Westenberg initiates coverage on Bio-Techne Corp. (NASDAQ: TECH) with a Neutral rating and a price target of $65.00.

Form 4 BIO-TECHNE Corp For: Jun 02 Filed by: Crouse Steven C.

Thu, 04 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260604/26606131.html

Form 4 BIO-TECHNE Corp For: Jun 02 Filed by: Crouse Steven C.

Thu, 04 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260604/26606131.html

Bio-Techne and Refeyn launch integrated workflow for antibody analysis

Thu, 04 Jun 2026 06:31:05 -0400

Bio-Techne Corporation (NASDAQ: TECH) and Refeyn announced a new integrated workflow that combines imaged capillary isoelectric focusing fractionation with mass photometry technology for analyzing bispecific antibodies and biosimilars.

The workflow integrates Bio-Techne's R&D Systems MauriceFlex imaged capillary isoelectric focusing system with Refeyn's TwoMP mass photometry platform. The combination allows researchers to analyze charge heterogeneity alongside molecular weight and aggregation at single-molecule resolution in a four-hour process.

The MauriceFlex system separates and fractionates charge variants, while the TwoMP platform analyzes size distribution and aggregation using nanogram-level samples. The workflow enables direct characterization of aggregation and size within charge variants that were previously separated

Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

Thu, 04 Jun 2026 06:30:00 -0400

New integrated workflow combines icIEF fractionation and mass photometry
Enables direct characterization of aggregation and size within icIEF-resolved charge variants
Four-hour workflow reduces development risk and accelerates biosimilar manufacturing

MINNEAPOLIS and OXFORD, England, June 4, 2026 /PRNewswire/ -- Bio‑Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first‑of‑its‑kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars.

By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system

Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

Thu, 04 Jun 2026 06:30:00 -0400

New integrated workflow combines icIEF fractionation and mass photometry
Enables direct characterization of aggregation and size within icIEF-resolved charge variants
Four-hour workflow reduces development risk and accelerates biosimilar manufacturing

By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system

Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

Thu, 04 Jun 2026 06:30:00 -0400

New integrated workflow combines icIEF fractionation and mass photometry
Enables direct characterization of aggregation and size within icIEF-resolved charge variants
Four-hour workflow reduces development risk and accelerates biosimilar manufacturing

By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system

Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

Thu, 04 Jun 2026 06:30:00 -0400

New integrated workflow combines icIEF fractionation and mass photometry
Enables direct characterization of aggregation and size within icIEF-resolved charge variants
Four-hour workflow reduces development risk and accelerates biosimilar manufacturing

By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system

Form SD BIO-TECHNE Corp

Mon, 01 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260601/26584239.html

Form SD BIO-TECHNE Corp

Mon, 01 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260601/26584239.html

RBC Capital Assumes Bio-Techne Corp. (TECH) at Outperform

Thu, 14 May 2026 16:27:41 -0400

(Updated - May 14, 2026 4:27 PM EDT)

RBC Capital analyst Dan Leonard assumes coverage on Bio-Techne Corp. (NASDAQ: TECH) with a Outperform rating and a price target of $62.00.

The analyst comments "We resume coverage of Bio-Techne (TECH) with an Outperform rating and $62 price target, which reflects our confidence that sales growth will rebound and company's planned acquisition of Wilson Wolf is underappreciated. Bio-Techne is the most levered to the improved biotech funding environment in our coverage. While waiting for the market rebound, the company is not sitting still, but rather executing on multiple initiatives to improve its business mix

RBC Capital Assumes Bio-Techne Corp. (TECH) at Outperform

Thu, 14 May 2026 16:27:41 -0400

(Updated - May 14, 2026 4:27 PM EDT)

RBC Capital analyst Dan Leonard assumes coverage on Bio-Techne Corp. (NASDAQ: TECH) with a Outperform rating and a price target of $62.00.

Form 4 BIO-TECHNE Corp For: May 08 Filed by: Herr Amy E.

Tue, 12 May 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260512/26477538.html

Form 4 BIO-TECHNE Corp For: May 08 Filed by: Herr Amy E.

Tue, 12 May 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260512/26477538.html

Form 144 BIO-TECHNE Corp Filed by: Herr Amy E.

Fri, 08 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260508/26461503.html

Form 144 BIO-TECHNE Corp Filed by: Herr Amy E.

Fri, 08 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260508/26461503.html

Form 4 BIO-TECHNE Corp For: May 05 Filed by: Hippel James

Thu, 07 May 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260507/26455352.html

Form 4 BIO-TECHNE Corp For: May 05 Filed by: Hippel James

Thu, 07 May 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260507/26455352.html

Form 4 BIO-TECHNE Corp For: May 05 Filed by: Bohnen Shane

Thu, 07 May 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260507/26455332.html

Form 4 BIO-TECHNE Corp For: May 05 Filed by: Bohnen Shane

Thu, 07 May 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260507/26455332.html

Form 4 BIO-TECHNE Corp For: May 05 Filed by: Kelderman Kim

Thu, 07 May 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260507/26455303.html

Form 4 BIO-TECHNE Corp For: May 05 Filed by: Kelderman Kim

Thu, 07 May 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260507/26455303.html

Bio-Techne Corp. (TECH) PT Lowered to $62 at Wells Fargo

Thu, 07 May 2026 08:25:05 -0400

Wells Fargo analyst Brandon Couillard lowered the price target on Bio-Techne Corp. (NASDAQ: TECH) to $62.00 (from $76.00) while maintaining a Overweight rating.